Select Language

LRRC32

LRRC32 Overview

English Name	Transforming growth factor beta activator LRRC32	Approved Drugs	0
Drugs in Clinical Trials	7	Target Synonym	Leucine Rich Repeat Containing 32，D11S833E，Garpin，Leucine-Rich Repeat-Containing Protein 32，LRRC32，Transforming Growth Factor Beta Activator LRRC32，GARP，Glycoprotein A Repetitions Predominant
Highest Development Stage	Phase 3 Clinical

English Name	Transforming growth factor beta activator LRRC32
Target Synonym	Leucine Rich Repeat Containing 32，D11S833E，Garpin，Leucine-Rich Repeat-Containing Protein 32，LRRC32，Transforming Growth Factor Beta Activator LRRC32，GARP，Glycoprotein A Repetitions Predominant
Approved Drugs	0
Drugs in Clinical Trials	7
Highest Development Stage	Phase 3 Clinical

LRRC32 Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
Fc Tag (1)
Conjugate
Unconjugated (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
LR2-H5256	Human	HEK293	Human LRRC32 / GARP / Garpin Protein, Fc Tag

Total: 1

LRRC32 Background

Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells. LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells. The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation.

LRRC32 Synonyms

GARP,Garpin,D11S833E

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Livmoniplimab	MGH-8; AGRX-115; ABBV-151; MHG-8; ARGX-115	Phase 3 Clinical	Argenx Se	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Solid tumours	Details
Anti-GARP Chimeric Antigen Receptor T Cell Therapy (Ohio State University Comprehensive Cancer Center)		Phase 1 Clinical	Ohio State University Comprehensive Cancer Center	Glioma	Details
PBA-0111	PBA-0111	Phase 1 Clinical	Pure Biologics SA	Sarcoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms	Details
HLX-6018	HLX-6018; HLX6018	Phase 1 Clinical		Idiopathic Pulmonary Fibrosis	Details
JYB-1907	JYB-1907	Phase 1 Clinical	Jiangxi Jemincare Group Co Ltd	Solid tumours	Details
DS-1055	DS-1055; DS-1055a	Phase 1 Clinical	Daiichi Sankyo Co Ltd	Neoplasms; Solid tumours	Details
HLX-60	HLX-60	Phase 1 Clinical		Lymphoma; Solid tumours	Details